Skip to main content

Semaglutide Seems Beneficial for Comorbid T2DM, Tobacco Use Disorder

Medically reviewed by Carmen Pope, BPharm. Last updated on July 30, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 29, 2024 -- For patients with type 2 diabetes mellitus (T2DM) and tobacco use disorder (TUD), new use of semaglutide is associated with lower risk of TUD-related health care measures compared with other antidiabetes medications, according to a study published online July 30 in the Annals of Internal Medicine.

William Wang, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues examined the association of semaglutide with TUD-related health care measures in patients with comorbid T2DM and TUD in an emulation target trial. Seven target trials were emulated among eligible patients comparing the new use of semaglutide with seven other antidiabetes medications. The analyses included 222,942 new users of antidiabetes medications, of whom 5,967 were new users of semaglutide.

The researchers found that compared with other antidiabetes medications, semaglutide was associated with a significantly lower risk for medical encounters for TUD diagnosis, with the strongest association compared with insulins (hazard ratio, 0.68) and the weakest, but statistically significant, association compared with other glucagon-like peptide 1 receptor agonist medications (hazard ratio, 0.88). Reduced smoking cessation medication prescription and reduced counseling were seen in association with semaglutide. Patients with and without a diagnosis of obesity had similar findings.

"Although our results may be consistent with the hypothesis that semaglutide might be beneficial for smoking cessation, study limitations preclude firm conclusions and should not be interpreted to justify clinicians' use of semaglutide off-label for smoking cessation," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Nicotine Pouch Use in Teens Linked to Lower Risk for Continued Vaping

MONDAY, May 19, 2025 -- Nicotine pouch use in adolescence is associated with a lower likelihood of continued vaping, according to a study published online May 19 in...

GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression

MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...

Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis

TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.